Famotidine Powder, For Suspension
NDC 42571-433
Product Information
Famotidine is a ANDA-approved product labeled by Micro Labs Limited. This medication is typically used as a histamine h2 receptor antagonists [moa]. It is supplied as a white powder, for suspension for oral administration. This product entry covers the primary NDC 42571-433 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
STRAWBERRY (C73417)
Code Structure Chart
Product Details
What is NDC 42571-433?
What are the uses of this product?
What are Active Ingredients of this product?
- FAMOTIDINE 40 mg/5mL - A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- FAMOTIDINE (UNII: 5QZO15J2Z8)
- FAMOTIDINE (UNII: 5QZO15J2Z8) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)
- POWDERED CELLULOSE (UNII: SMD1X3XO9M)
- SUCROSE (UNII: C151H8M554)
- XANTHAN GUM (UNII: TTV12P4NEE)
- SODIUM BENZOATE (UNII: OJ245FE5EU)
- METHYLPARABEN SODIUM (UNII: CR6K9C2NHK)
- PROPYLPARABEN SODIUM (UNII: 625NNB0G9N)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 310274 - famotidine 40 MG in 5 mL Oral Suspension
- RxCUI: 310274 - famotidine 8 MG/ML Oral Suspension
- RxCUI: 310274 - famotidine 40 MG per 5 ML Oral Suspension
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.